What is Wedbush's Estimate for Shattuck Labs Q3 Earnings?

Key Points

• Wedbush forecasts Shattuck Labs, Inc. to post Q3 2025 earnings of ($0.11) per share, with a full-year estimate of ($1.48) EPS and an "Outperform" rating with a target price of $4.00.
• Recent analyst reports indicate mixed ratings, with two firms giving a Strong Buy and Buy ratings, while others have issued a Hold rating, resulting in an average rating of Moderate Buy.
• Insider activity has increased as Director Mona Ashiya purchased 6.3 million shares at $0.87 each, indicating significant confidence in the company's future.

Shattuck Labs, Inc. (NASDAQ:STTK - Free Report) - Investment analysts at Wedbush issued their Q3 2025 earnings per share (EPS) estimates for Shattuck Labs in a report released on Monday, September 8th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings per share of ($0.11) for the quarter. Wedbush currently has a "Outperform" rating and a $4.00 target price on the stock. The consensus estimate for Shattuck Labs' current full-year earnings is ($1.48) per share. Wedbush also issued estimates for Shattuck Labs' Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.61) EPS, Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.32) EPS, FY2027 earnings at ($0.28) EPS, FY2028 earnings at ($0.27) EPS and FY2029 earnings at ($0.39) EPS.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.01.

Other equities research analysts have also issued research reports about the company. Leerink Partners dropped their price objective on Shattuck Labs from $4.00 to $2.00 and set an "outperform" rating for the company in a research note on Thursday, August 14th. Wall Street Zen raised Shattuck Labs from a "sell" rating to a "hold" rating in a research note on Saturday. Finally, Needham & Company LLC reissued a "hold" rating on shares of Shattuck Labs in a research note on Thursday, August 14th. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $4.00.

Shattuck Labs Price Performance

Shares of Shattuck Labs stock traded down $0.08 during trading hours on Wednesday, reaching $1.84. The company had a trading volume of 183,113 shares, compared to its average volume of 934,061. The firm has a market cap of $88.14 million, a PE ratio of -1.52 and a beta of 1.64. Shattuck Labs has a one year low of $0.69 and a one year high of $3.95. The business has a fifty day simple moving average of $1.00 and a 200 day simple moving average of $1.01.

Institutional Trading of Shattuck Labs

Several large investors have recently bought and sold shares of STTK. Northern Trust Corp boosted its position in Shattuck Labs by 9.2% during the 4th quarter. Northern Trust Corp now owns 353,616 shares of the company's stock valued at $428,000 after acquiring an additional 29,870 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new stake in shares of Shattuck Labs in the 4th quarter worth approximately $45,000. Bank of America Corp DE boosted its position in shares of Shattuck Labs by 135.0% in the 4th quarter. Bank of America Corp DE now owns 187,089 shares of the company's stock worth $226,000 after purchasing an additional 107,491 shares in the last quarter. Deutsche Bank AG boosted its position in shares of Shattuck Labs by 476.4% in the 4th quarter. Deutsche Bank AG now owns 116,868 shares of the company's stock worth $141,000 after purchasing an additional 96,594 shares in the last quarter. Finally, Millennium Management LLC boosted its position in shares of Shattuck Labs by 37.0% in the 4th quarter. Millennium Management LLC now owns 201,214 shares of the company's stock worth $243,000 after purchasing an additional 54,322 shares in the last quarter. 58.74% of the stock is owned by institutional investors.

Insider Activity at Shattuck Labs

In other news, Director Orbimed Advisors Llc acquired 6,306,127 shares of the business's stock in a transaction on Monday, August 25th. The shares were acquired at an average cost of $0.87 per share, with a total value of $5,486,330.49. Following the transaction, the director owned 5,255,106 shares in the company, valued at $4,571,942.22. The trade was a -600.00% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Mona Ashiya acquired 6,306,127 shares of the business's stock in a transaction on Monday, August 25th. The shares were purchased at an average cost of $0.87 per share, for a total transaction of $5,486,330.49. Following the completion of the transaction, the director owned 5,255,106 shares in the company, valued at approximately $4,571,942.22. This represents a -600.00% increase in their position. The disclosure for this purchase can be found here. Insiders own 12.00% of the company's stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.